[#item_full_content]
DERIO, Spain–(BUSINESS WIRE)–ONCOMATRYX, a Spanish biopharmaceutical company developing Quantum ADCs against the tumor microenvironment, has successfully raised $67 million to foster the clinical development of novel candidates. The funding round was led by the company’s institutional investors, including a $28 million strategic investment from the Spanish Government through Centro para el Desarrollo Tecnologico e Innovacion (CDTI), $18 million from Kutxa Fundazioa, $12 million from the Basqu